Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases. Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people.
We own the exclusive worldwide rights to alicaforsen, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases. We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI dysmotility disorders in rare disease patient populations.
We own the exclusive worldwide rights to alicaforsen, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases. We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI dysmotility disorders in rare disease patient populations.
Services
Atlantic Healthcare plc is headquartered near Cambridge (UK) and operates across North America and Europe. Our experienced Leadership Team and international Board of Directors have deep roots in the pharmaceutical industry and ambitious plans to develop and commercialize products that can improve the lives of patients, by providing clinicians with safe and effective treatments at cost-effective prices.
We are advancing alicaforsen for the treatment of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis. In addition, we are advancing three renzapride clinical programmes for the treatment of GI dysmotility. Alicaforsen is a novel antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation.
Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases.
Atlantic Healthcare has a committed investor base and an experienced international Board and Leadership Team, with a clear and cost-effective commercialization strategy. We intend to commercialize our products in Europe and the U.S. using a specialist sales team targeting gastroenterologists in hospitals and specialists care centres.
Reviews
Be the first to review Atkinson Visiting Nurses Service.
Write a Review